LMDX News and Press, LumiraDx Limited From 12/23/21

LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking - Rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for the simultaneous detection and differen...

LumiraDx (NASDAQ:LMDX) announces a partnership with digital health non-profit Audere, to offer a self-collected COVID-19 nasal specimen collection kit that has been authorized for use with the LumiraDx SARS-CoV-2 RNA STAR Complete assay to process self-collected samples. LMDX shares rise...

LumiraDx Fast Lab Solutions Partners with Audere for At-Home Self- Collection Solution for use with SARS-CoV-2 RNA STAR Complete Audere's HealthPulse@home further supports LumiraDx's mission to broaden access to support variety of testing needs PR Newswire LONDON ...

LumiraDx (NASDAQ:LMDX) is trading ~8.5% higher in the pre-market after the company announced that the FDA reissued the Emergency Use Authorization (EUA) for its COVID-19 testing solution SARS-CoV-2 RNA STAR Complete. The revised EUA includes the testing of asymptomatic individuals a...

FDA Reissues LumiraDx Fast Lab Solutions' EUA for SARS CoV-2 RNA STAR Complete Molecular Reagents to Allow High Throughput and Asymptomatic Testing Solutions PR Newswire LONDON , Dec. 1, 2021 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX) announced today ...

Shares of LumiraDx Limited (NASDAQ:LMDX) traded at a new 52-week high today of $10.89. Approximately 1.7 million shares have changed hands today, as compared to an average 30-day volume of 492,000 shares. There is potential upside of 0.1% for shares of LumiraDx Limited based on a current...

Shares of LumiraDx (NASDAQ:LMDX) closed up 9% today and reached a 52-week high of $10.73, just two days after Evercore ISI initiated the stock with a buy rating. The firm has a $20 price target on shares (~91% upside based on today's closing price). Analyst Vijay Kumar believes that...

LumiraDx Limited’s (LMDX) Q3 2021 Earnings Conference Call November 10, 2021 8:00 P.M. ET Company Participants Colleen McMillen - Vice President of Communications Ron Zwanziger - Chief Executive Officer Dorian LeBlanc - Chief Financial Officer Pooja Pathak - Chief Product Officer Confe...

LumiraDx (NASDAQ:LMDX): Q3 Non-GAAP EPS of $0.16 beats by $0.35; GAAP EPS of $0.46 beats by $0.63. Revenue of $109.08M (+683.6% Y/Y) beats by $8.41M. Press Release For further details see: LumiraDx EPS beats by $0.35, beats on revenue

LumiraDx Reports Third Quarter 2021 Financial Results Strong Revenue Growth and Strategic Progress on Platform, Products and Pipeline PR Newswire LONDON , Nov. 10, 2021 /PRNewswire/ -- LumiraDx (Nasdaq:LMDX), a next-generation point of care (POC) diagnos...